Recurrent, multisystem angioedema induced by 5-azacitidine.

IF 1 4区 医学 Q4 ONCOLOGY
Ruba Alchaikh Hassan, Shiva Salmasi, Zahra Ghafarzadeh, Constantin A Dasanu
{"title":"Recurrent, multisystem angioedema induced by 5-azacitidine.","authors":"Ruba Alchaikh Hassan, Shiva Salmasi, Zahra Ghafarzadeh, Constantin A Dasanu","doi":"10.1177/10781552241288475","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>5-azacitidine is a hypomethylating agent (HMA) used for treating myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs). Common side effects include myelosuppression, nausea and injection site reactions. Serious allergic reactions are rare with this class of agents.</p><p><strong>Case report: </strong>We describe a 71-year-old man with MDS/MPN who developed repeated episodes of angioedema after starting treatment with subcutaneous 5-azacitidine. Angioedema involved multiple body areas including the neck, genitalia, lower back and gastrointestinal system. Causality assessment linked this entity to 5-azacitidine via the Naranjo nomogram questionnaire, by scoring 9.</p><p><strong>Management and outcome: </strong>5-azacitidine was discontinued due to recurrent episodes of angioedema that occurred even after dose reduction. Steroids were helpful in terms of reversing this reaction. Afterwards, no further episodes of angioedema have been documented. The patient's thrombocytosis is currently well-controlled with low dose hydroxyurea.</p><p><strong>Discussion/conclusion: </strong>We report herein a unique case of recurrent, multisystem angioedema likely related to 5-azacitidine. The exact mechanism of azacitidine-induced angioedema is not currently known. Symptoms, clinical findings and timing of presentation are not always clear-cut, and it may take more than one cycle of 5-azacitidine before the diagnosis is made. Supportive and symptomatic treatment will be provided based on the severity of the reaction. Future studies may offer more insights into the mechanism underlying this rare and serious, yet intriguing side effect.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241288475"},"PeriodicalIF":1.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241288475","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: 5-azacitidine is a hypomethylating agent (HMA) used for treating myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs). Common side effects include myelosuppression, nausea and injection site reactions. Serious allergic reactions are rare with this class of agents.

Case report: We describe a 71-year-old man with MDS/MPN who developed repeated episodes of angioedema after starting treatment with subcutaneous 5-azacitidine. Angioedema involved multiple body areas including the neck, genitalia, lower back and gastrointestinal system. Causality assessment linked this entity to 5-azacitidine via the Naranjo nomogram questionnaire, by scoring 9.

Management and outcome: 5-azacitidine was discontinued due to recurrent episodes of angioedema that occurred even after dose reduction. Steroids were helpful in terms of reversing this reaction. Afterwards, no further episodes of angioedema have been documented. The patient's thrombocytosis is currently well-controlled with low dose hydroxyurea.

Discussion/conclusion: We report herein a unique case of recurrent, multisystem angioedema likely related to 5-azacitidine. The exact mechanism of azacitidine-induced angioedema is not currently known. Symptoms, clinical findings and timing of presentation are not always clear-cut, and it may take more than one cycle of 5-azacitidine before the diagnosis is made. Supportive and symptomatic treatment will be provided based on the severity of the reaction. Future studies may offer more insights into the mechanism underlying this rare and serious, yet intriguing side effect.

5-氮杂胞苷诱发复发性多系统血管性水肿。
简介5-azacitidine 是一种低甲基化药物(HMA),用于治疗骨髓增生异常综合征(MDS)和某些骨髓增生性肿瘤(MPN)。常见的副作用包括骨髓抑制、恶心和注射部位反应。该类药物很少出现严重的过敏反应:我们描述了一名患有 MDS/MPN 的 71 岁男性患者,他在开始接受皮下注射 5-azacitidine 治疗后反复出现血管性水肿。血管性水肿累及身体多个部位,包括颈部、生殖器、下背部和胃肠道系统。通过纳兰霍(Naranjo)提名图问卷进行的因果关系评估将该病症与 5-azacitidine 联系起来,评分为 9 分:由于血管性水肿反复发作,即使在减少剂量后仍会发生,因此停用了 5-阿扎胞苷。类固醇类药物有助于逆转这种反应。此后,再也没有发生过血管性水肿。目前,使用小剂量羟基脲后,患者的血小板减少得到了很好的控制:我们在此报告了一例独特的复发性多系统血管性水肿病例,可能与 5-阿扎胞苷有关。目前尚不清楚阿扎胞苷诱发血管性水肿的确切机制。症状、临床表现和发病时间并不总是很明确,可能需要服用一个周期以上的 5-azacitidine 后才能确诊。将根据反应的严重程度提供支持性和对症治疗。未来的研究可能会对这一罕见、严重但有趣的副作用的发生机制提供更多的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信